Net Loss per Share (Tables)

12 Months Ended

Dec. 31, 2017

Reconciliation of the Numerator and Denominator Used in the Calculation of Basic and Diluted Net Loss per Share of Class A Common Stock

A reconciliation of the numerator and denominator used in the calculation of basic and diluted net loss per share of Class A Common Stock is as follows (amounts in thousands, except per share amounts):

	Year Ended December 31,
	2017			2016			2015
Numerator:
Net loss	$	(54,647	)	$	(55,353	)	$	(41,107	)
Less: Net loss attributable to noncontrolling interests		(38,503	)		(39,001	)		(13,609	)
Net loss attributable to vTv Therapeutics Inc., basic and diluted	$	(16,144	)	$	(16,352	)	$	(27,498	)
Denominator:
Weighted-average vTv Therapeutics Inc. Class A Common Stock, basic and diluted		9,693,254			9,545,527			8,276,520
Net loss per share of vTv Therapeutics Inc. Class A Common Stock, basic and diluted	$	(1.67	)	$	(1.71	)	$	(3.32	)

Schedule of Potentially Dilutive Securities Not Included in Calculation of Dilutive Net Loss per Share

Potentially dilutive securities not included in the calculation of dilutive net loss per share are as follows:

	Year Ended December 31,
	2017		2016		2015
Class B Common Stock ⁽¹⁾		23,119,246		23,119,246		23,655,814
Common stock options granted under the Plan		1,960,732		1,096,101		971,934
Restricted stock units		35,000		—		—
Common stock options granted under the Letter Agreement		2,283,105		—		—
Common stock warrants		388,853		152,580		—
Total		27,786,936		24,367,927		24,627,748

(1)

Shares of Class B Common Stock do not share in the Company’s earnings and are not participating securities. Accordingly, separate presentation of loss per share of Class B Common Stock under the two-class method has not been provided. Each share of Class B Common Stock (together with a corresponding vTv Unit) is exchangeable for one share of Class A Common Stock.